Background The inclusion of future medical costs in cost-effectiveness analyses remains a controversial issue. The impact of capturing future medical costs is likely to be particularly important in patients with cancer where costly lifelong medical care is necessary. The lack of clear, definitive pharmacoeconomic guidelines can limit comparability and has implications for decision making. Objective The aim of this study was to demonstrate the impact of incorporating future medical costs through an applied example using original data from a clinical study evaluating the cost effectiveness of a sepsis intervention in cancer patients. Methods A decision analytic model was used to capture quality-adjusted life-years (QALYs) and lifetime costs of cancer patients from an Australian healthcare system perspective over a lifetime horizon. The evaluation considered three scenarios:
Introduction
The inclusion of future costs in cost-effectiveness analysis (CEA) is a contentious issue, particularly when costs are unrelated to the intervention being evaluated. Fundamentally, the aim of CEA is to aid decision makers to optimally allocate scarce healthcare resources to maximise population health gains. To achieve this, appropriate costs and benefits need to be accounted for in order to determine if the benefits outweigh the costs. Much health economics research has contributed to a better understanding of quantifying and extrapolating outcomes [utilities, life-years and qualityadjusted life-years (QALYs)] in CEA to fully capture the lifetime benefits of an intervention. Therefore, it has been argued that the same philosophy should be applied to costs (i.e. inclusion of all costs necessary to attain the lifetime benefits captured) for consistency [1, 2] and to achieve utility maximisation [3] .
The inclusion of related medical costs, those that are a direct consequence of the intervention under study, is common practice in economic evaluations and the general agreement is that they should be accounted for. However, there is much debate around the inclusion of unrelated future medical costs. These are healthcare costs that are expected to be incurred as a consequence of added life-years resulting from the intervention; that is, not directly related to the intervention but conditional on survival as a result of the intervention. Therefore, the impact of future costs is most relevant to life-extending technologies where the omission of medical costs incurred in the additional surviving years could risk overstating the cost effectiveness of these interventions compared with those that improve quality of life. This relative overstating of cost effectiveness could ultimately result in loss of population health benefits [4] . Conversely, some have reasoned that omission of future costs 1 is unlikely to have any substantial impact as long as decisions are made based on consistent use of cost data [5, 6] . Costs in health economics are, however, linked to the context of a decision so it is critical that information about inputs, timing, technology and who the decision maker is are all accurately reflected [7] . Others have argued the case that to include future costs would result in inequitable outcomes; for example, in patient populations where future medical costs inevitably include expensive ongoing healthcare costs such as dialysis costs for chronic kidney disease patients [8, 9] .
Although it appears that the growing consensus is to include all future medical costs [10, 11] , variations in pharmacoeconomic guidelines persist. Many agencies involved with health technology assessment for reimbursement recommend that only costs related to the intervention studied should be included. For example, National Institute for Health and Care Excellence (NICE) in the UK recommends that "costs that are considered to be unrelated to the condition or technology of interest should be excluded" [12] . Likewise, in Australia, the Pharmaceutical Benefits Advisory Committee (PBAC) suggests similar recommendations [13] . However, this has been challenged by the recent recommendation of the second US Panel on Cost-effectiveness in Health and Medicine. They propose that all costs both present and future, whether related or unrelated, should be included in cost-effectiveness analyses [14] . In recent years, there has also been a change in national guidelines for technology appraisals to include all future costs such as those from the Netherlands [15] . Given the lack of agreement or clear methodological recommendations, large variations in the incorporation of costs across CEAs is unsurprising and can limit the comparability and interpretation of results [16, 17] .
The impact of capturing future medical costs is likely to be particularly important in patients with cancer as treatment costs are higher than for many other diseases [19] [20] [21] . Costs are also rising rapidly with the availability of new technologies, particularly those that improve survivorship [22] . It is also important to recognise that the care of cancer patients does not only involve the treatment of primary disease, but also requires management of complications arising that can impact survival [23] . To most, it may seem obvious that the inclusion of more cost categories or future costs would necessarily increase the incremental cost-effectiveness ratio (ICER), particularly for life-prolonging interventions due to added life-years. This has been demonstrated in a review of cancer-related CEAs for interventions that extend life expectancy where the authors retrospectively recalculated alternative ICERs based on assumptions regarding inclusion of future related and unrelated costs [17] . Further, none of the cost-effectiveness studies reviewed included unrelated future medical costs and one-third did not include medical costs related to the disease. ICERs can vary considerably depending on the costing methodology employed, which can have important decision-making implications, particularly in the funding of new cancer pharmacotherapies.
Cancer care costs are substantial at the time of diagnosis, and lifetime cancer care will continue to impact healthcare costs throughout the remaining life of the patient [24] [25] [26] [27] . Furthermore, there can be important differences in treatment costs as these can vary depending on the time since diagnosis, stage and cancer type [26] [27] [28] [29] , resulting in variations in healthcare costs. Therefore, if future medical costs are to be incorporated into CEA, an improved understanding of economic evaluation methodology and the consequences for priority setting (i.e. the degree of variation in cost-effectiveness ratios for treatment of patients with different types of cancer) is needed.
The objective of this study was to demonstrate the impact of incorporating future medical costs through an applied example using original data from an Australian clinical study evaluating the impact of sepsis intervention in cancer patients (see Appendix 2 in the Electronic Supplementary Material (ESM) for more details on sepsis management and an overview of the Australian healthcare system). To address this question, an economic evaluation considering only intervention costs (no future medical costs) was undertaken and compared with evaluations that considered ongoing lifetime medical costs related and unrelated to cancer. As survival and lifetime costs between cancer types vary, the analysis was also conducted across different cancers to better understand the implications for CEA. Information from this study will assist decision making for clinicians and policymakers and also add to the understanding of how incorporation of future costs impacts resource allocation for cancer interventions.
Methods

Study Setting
An economic evaluation of a hospital-wide sepsis pathway intervention (SP) in a cancer hospital was performed comparing the cost and outcomes of patients pre-and postpathway intervention. The analysis was undertaken from the perspective of the healthcare system/payer. Details of the implementation study including identification of sepsis and non-sepsis cohorts, and the clinical outcomes have been described elsewhere [30, 31] . Briefly, the SP intervention supported nurse-initiated sepsis care, early medical review, and prompt antibiotic and fluid resuscitation and was implemented in Peter MacCallum Cancer Centre (PMCC), Melbourne Australia in March 2013. Two patient cohorts were compared; patients in the SP cohort (post-intervention) and non-SP cohort (pre-intervention). Detailed hospitalisation costs were available for 275 patients, 184 (86.8%) and 91 (82.0%) in the SP and non-SP cohorts, respectively. Patient demographic and clinical characteristics are presented in Appendix 3 Table 1 in the ESM. For more details on the study setting and costing of the intervention see Appendix 3 and 4 in the ESM.
Overview of Analysis
To demonstrate and quantify the implications of different assumptions regarding the incorporation of future medical costs on the cost effectiveness of the SP intervention, the evaluation was conducted under three scenarios reflecting the different sets of costs incorporated in the analysis.
(1) Intervention-related costs-no future medical costs. (2) Excess cancer costs-intervention and lifetime diseaserelated costs. (3) All future costs-intervention, disease-related and all other health care costs.
Model Structure
A decision analytic model was developed to capture both the QALYs and lifetime costs of cancer patients. The lifetime model consists of two parts: a decision tree and a cohort time-dependent Markov model to capture the longterm impact (lifetime modelling) of the SP intervention (Appendix 5, Fig. 1 in the ESM). The decision tree represents the initial acute hospitalisation episode as observed and measured in the implementation study [31] . Survivors at 30 days enter the life-long Markov model that consists of a simple two-state model (Alive and Dead) to extrapolate full life expectancy. The combination of a decision tree and Markov model captures the short-term mortality of the initial episode, reflecting the limited duration of most clinical studies and the subsequent risk of death of survivors by extrapolation of survival and costs over a 40-year lifetime time horizon [32, 33] .
Data Inputs
Cancer patients were assumed to be newly diagnosed and clinical effectiveness of the intervention (30-day mortality) as observed in the clinical study was applied similarly across cancer types. Future medical costs due to cancer (excess cancer costs) and other (unrelated) healthcare costs were sourced from New Zealand data published by Blakely et al. [28, 34] , providing reliable national estimates derived from large population-linked data. As robust Australian population cost estimates for lifetime medical costs were not available for the variety of cancers considered, this cost data was deemed to be most appropriate. Further, similarities between the Australian and New Zealand healthcare systems and in their hospital funding systems [35] makes this a reasonable source. Both countries also share treatment guidelines; for example, for melanoma [36] . Cancer costs were calculated based on coefficients published by the referenced source, which provided specific costs for different cancer types, and by time since diagnosis. This allowed the incorporation of detailed lifetime cost information into the model appropriate for the evaluation of future medical costs. The method of deriving specific cancer costs is described in Appendix 6, see ESM. Death transition costs were included in the model, reflecting the substantial and elevated healthcare costs incurred in the months immediately prior to death. All parameter inputs were entered as probability distributions to capture uncertainty as listed in Table 1 . Data for the decision tree were sourced from the clinical implementation study, reflecting the average survival probabilities and hospitalisation costs of both cohorts. The base-case analysis utilised mortality rates and lifetime cancer costs for all cancers combined. A scale-up factor [37] was used to inflate the mortality rate, reflecting the impact of sepsis on patient mortality in a cancer-specific population. This was calculated using relative risks sourced from a large cohort study examining excess mortality risk in sepsis patients [38] and was assumed to last up to 2 years following the sepsis episode concurrent with reported findings in Australia [39] . Excess mortality rates due to cancer were estimated from relative survival data sourced from the Australian Institute of Health and Welfare (AIHW) [40] , which publishes national health statistics. The method of estimating mortality rate is described in Appendix 7 in the ESM.
To calculate QALYs, time spent in the Alive health state (i.e. life-years gained) was multiplied by assigning sepsis-specific utility values. Utilities up to 5 years postsepsis were sourced from published studies evaluating long-term quality of life of critically ill patients with cancer or severe sepsis [41, 42] .
Analytical Methods
The model was run over a lifetime horizon with monthly cycles for a cohort with a starting age of 60 years, reflecting the average age of patients in the implementation study. Half-cycle corrections were applied. Probabilistic sensitivity analysis (PSA) was undertaken by running 10,000 simulations of lifetime modelling for the two cohorts. A series of one-way sensitivity analyses was also undertaken to explore the implications of the assumptions made and data sources used in the model. Cost-effectiveness acceptability curves were used to present the uncertainty in cost effectiveness. Net monetary benefit (NMB) was also calculated to further elucidate differences across costing scenarios and cancer types assuming a plausible threshold of $50,000 in Australia [43] .
Both the costs and benefits were discounted at 5% annually as per Australian Pharmaceutical Benefits Advisory Committee recommendations [13] and were varied in sensitivity analyses. All costs are expressed in 2017 Australian dollars adjusted using the Consumer Price Index and purchasing power parities from the Australian Bureau of Statistics [44] and Organisation for Economic Co-operation and Development (OECD) [45] , respectively. Reporting follows the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) consolidated health economic evaluation reporting standards guideline [46] (Appendix 1 in the ESM).
As significant heterogeneity exists between cancer types, there is value in investigating cost effectiveness within a disease [47] . Therefore, in addition to the base-case analysis (all cancers combined), the impact of future medical costs was similarly conducted for a number of the most commonly diagnosed cancers. All costs and mortality inputs (Appendix 5, Table 3 in the ESM) were cancer specific as obtained from sources referenced above. All original data were analysed using STATA statistical software (version 14.0, Texas, USA) and the CEA model was built using TreeAge Pro 2017 (Massachusetts, USA).
Results
Cost-Effectiveness Analysis
Comparisons of cost-effectiveness results for all three scenarios are presented in Table 2 . Incremental costs and ICERs increased as more cost resource categories were included into the analysis. In scenario 1, when considering intervention-related costs only (no future medical costs), the SP was a dominant strategy (cheaper and more effective than the non-SP cohort). This changed for scenarios 2 and 3. In the 'all future healthcare costs' scenario, the ICER increased to $7526.09/QALY gained. The incorporation of future costs also had an impact on the probability of the SP implementation being cost effective at a willingness-to-pay (WTP) threshold below $25,000/QALY, as shown in Fig. 1 .
Several one-way sensitivity analyses were conducted to test the robustness of the model and results are presented in Fig. 2 . Overall, the model was most sensitive to changes in the time horizon. The model was also sensitive to the discount rate, assumptions on prevalence and ongoing risk of sepsis. For instance, in comparison with the base-case ICER, when time horizon was reduced to 5 years in the model, the intervention became a dominant strategy and reducing the discount rate to 0% increased ICER to $10,992.87. Figure 3 shows the breakdown of lifetime costs and QALYs across different types of cancer. Intervention-related costs, composed predominantly of hospitalisation costs (blue bars), were higher for the non-SP cohort than the SP cohort; therefore, the intervention appeared to be a dominant strategy across all cancer types when no future costs were taken into account. With the inclusion of future costs, total lifetime healthcare costs varied depending on the type of cancer (Fig. 3) . As more cost sets were incorporated into the analysis, incremental costs increased and differed across cancers depending on the cost of managing the respective cancers and survivorship. The full set of results can be found in Appendix 8, Table 4 in the ESM. The cost effectiveness of the SP intervention varied depending on the type of cancer and a similar trend of increasing ICERs was observed as future medical costs were included into the CEA analysis. Correspondingly, NMBs varied across cancer types and were substantially lower when future medical costs were included in the analysis (Appendix 8, Fig. 2 in the ESM). Figure 4 shows the cost-effectiveness acceptability curves with all costs included across different cancer types compared with the base case (all cancers combined). Heterogeneity across cancer types is evident and this had an impact on decision uncertainty. For example, at a WTP of $50,000/ QALY, the probability of a SP intervention being cost effective varied from 0.54 (leukaemia) to 0.70 (myeloma) to close to 1 for cancers such as breast, melanoma, prostate, colorectal and Hodgkin's lymphoma.
Analyses by Cancer Types and Future Costs
Discussion
This study demonstrated that the incorporation of future medical costs in the economic evaluation of a sepsis intervention in cancer patients can produce different cost-effectiveness results that may affect decisions made by policymakers. The CEA results based on intervention-related costs only showed that SP is highly likely to be a cost-saving dominant intervention. However, when extrapolated to lifetime with future medical costs, the intervention was no longer a dominant strategy but rather had an ICER of $7526/ QALY gained. Although the sepsis intervention remains cost effective by Australian standards [43] , the scenarios presented with and without future medical costs clearly demonstrate their impact and potential to result in different policy decisions depending on WTP thresholds.
Future costs are likely to have substantial impact for lifeextending interventions where survivors will require continuous and/or future medical attention that can translate into substantial ongoing healthcare costs. This has been demonstrated in disease areas such as type 1 diabetes mellitus [48] , chronic heart failure [49] and chronic kidney disease [8, 50] . This is similarly important in cancer patients who require lifelong medical care and surveillance, further adding to the burden on the patient and healthcare system. The exclusion of these costs means that decisions made using these costeffectiveness ratios will not adequately reflect a healthcare system perspective and are not considered in conjunction with the potential impact these interventions will have on healthcare budgets longer term [51] . For countries that do not explicitly incorporate future costs in funding decisions, it is still important to recognise the impact of these costs. If decision makers are to use CEAs to efficiently allocate resources within a fixed healthcare budget, then excluding future medical costs from analysis will not fully achieve this aim due to systematic biases that can arise from exclusion [4, 10] .
The difference in the resultant ICER due to the inclusion or exclusion of future healthcare costs could be large enough to influence decisions based on a fixed threshold as demonstrated by van Baal et al. [4] . When future costs are incorporated in our economic model, the impact is an increase in the ICER ranging from 92% to 290%. This change is similar to the impact observed in a review of cancer-related CEAs [17] that reported an average of 292% increase in ICER when incorporating future cost. A wide range of impacts have also been observed in other disease models (for example, a 57% decrease in type 1 diabetes intervention [48] and 1776% increase in end-stage renal disease care [50] , reflecting the broad range of methods and cost inputs. The extent of the impact of future costs will not only affect the resultant ICERs but the certainty under which decisions have to be made [52] . Additionally, as value-of-information analysis is increasingly becoming an important component in pharmacoeconomic assessments, further uncertainty generated from the inclusion of additional cost components has also shown to increase the expected value of perfect information (EVPI) [49] , which may result in the need to invest extra resources to eliminate all uncertainty in adopting the intervention. Given the large degree of variation observed, a much better understanding and consistency of how economic evaluations should be undertaken is warranted.
As cancer patients are unlikely to be a homogenous population, using cancer-specific inputs to extrapolate both outcomes and costs through lifetime modelling provided a better differentiation across cancer types compared with averaging inputs across all cancer patients. Importantly, results from the analysis showed that the impact of future costs differs across cancer types due to two aspects: cost of managing cancer and relative survival. Longer life expectancies did not necessarily result in greater lifetime healthcare costs (Fig. 3) . High ICERs were observed for cancers such as leukaemia, myeloma and brain were driven by high ongoing cancer costs and lower relative survival indicating immediate trade-offs between costs of intervening and level of benefits attainable.
These results have demonstrated that the distinct cancer characteristics matter, resulting in different cost-effectiveness results in subgroups according to the cancer type. Incorporating heterogeneity in economic evaluations has been controversial due to ethical considerations as subgrouping may lead to equity constraints in the provision of healthcare to certain populations. However, it is acknowledged that there is value in incorporating heterogeneity in economic evaluations [47, 53, 54] . Whilst it was useful to establish, these results are not intended to exclude certain groups from treatment as decisions on resource allocations are based on numerous factors other than cost effectiveness, such as clinical effectiveness and equity/ethical considerations, all of which need to be clear, transparent and acceptable. Therefore, there is value in incorporating heterogeneity in cost-effectiveness analyses to allow for better decision making [47, 55] and an understanding of how savings are being generated.
The ambiguity of what are related and unrelated medical costs has led to inconsistencies in the conduct of CEAs and interpretation of results [8, 16] . This study has demonstrated the impact that the type of cost included has on the ICER (Fig. 1) and, depending on the types of cost considered, it could have more impact for some cancers than others (Appendix 8 Fig. 3 and 4 in the ESM). In practice, how costs are classified is subject to the discretion of the analyst and it is often difficult to distinguish these costs [52, 56] . An alternative suggestion to overcome this conundrum is to ignore the distinction between related and unrelated, particularly if all future medical costs are to be included in the economic evaluation of life-extending technologies [57, 58] . As national guidelines are standards for performing economic evaluations in healthcare, it is therefore pertinent to advocate for clearer and consistent pharmacoeconomic guidelines around costing methodologies.
Limitations
The economic model represents a necessary simplification in capturing excess cancer mortality rates and lifetime healthcare costs. Despite this limitation, the model estimated a life expectancy of 20.05 years and 13.51 years for nonseptic breast and colon cancer patients, respectively, which is comparable to the published life expectancies calculated from the US Surveillance, Epidemiology, and End Results (SEER) registries [59] . Similarly, for lifetime cancer costs, estimates obtained were within the ranges of those published internationally [60, 61] . Simplifying assumptions were made to ensure comparable scenarios across different cancer types to better understand the impact of future costs. However, it is acknowledged that analysis by cancer stage and sepsis severity could be an important consideration that has not been adequately captured in this study, thus warranting future research. It would be vital to better understand the impact of sepsis and the intervention across various types and severities of cancer patients.
The lack of precise or reliable cost estimates can be problematic and the unavailability of cost data beyond the study period (e.g. post-hospitalisation) is often cited as a limitation [62] [63] [64] . While it is agreed that incorporating future medical costs into economic evaluations is not an easy task to accurately quantify and disaggregate, this analysis adds to the growing literature of economic evaluations that include future costs and has demonstrated the practicality of doing so. In countries like the Netherlands, where guidelines mandate the inclusion of such costs, resources to facilitate the inclusion of such costs have been developed and made publicly available [65] . The increasing availability of access to individual-level population-linked data from routine collection of health-related data has availed researchers to capture healthcare resource use and provide health system cost estimates by disease type, age, sex and proximity to death [26-28, 34, 66] . Another commonly employed approach to account for future medical costs is to use average health expenditure per person by age and sex [67, 68] . The availability of such data demonstrates the feasibility of including reasonable cost estimates into economic evaluations. Furthermore, Meltzer and Johansen [69] argue for the inclusion of rough estimates rather than the complete omission of such costs to avoid significant biases in cost-effectiveness results favouring life-extending technologies over those that improve quality of life.
Conclusion
This CEA provides evidence for potential bias in ICER results if future medical costs of surviving patients are not included in an economic evaluation. The impact of inclusion (excess cancer costs or all other healthcare costs) and noninclusion of future medical costs in the analysis are clearly distinguished, providing an important example for the economic evaluation methods literature. The analysis demonstrates cost effectiveness for cancer types, showing heterogeneity in cost-effectiveness results that will provide important input into treatment, planning and policy decisions.
